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Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease with various underlying pathophysiologic mechanisms which translate to endotypes, in contrast to clinical phenotypes or histological subtypes. Defining endotypes can help clinicians predict disease prognosis, select subjects
suitable for a specific therapy, and assess risks for comorbid conditions, including asthma. Therefore, with recent advancement of biologicals in CRS
clinical trials, endotyping can be a breakthrough in treating recalcitrant CRS. CRS is caused by dysregulated immunologic responses to external
stimuli, which induce various inflammatory mediators from inflammatory cells, including innate lymphoid cells (ILCs) and T lymphocytes as well as
epithelial cells. Thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, which are mainly secreted by epithelial cells in response to external stimuli, act on type 2 ILCs and T helper 2 (Th2) cells, inducing IL-4, IL-5, and IL-13. Local immunoglobulin E (IgE) production is also a signature
event in nasal polyps (NP). These inflammatory mediators are novel potential therapeutic targets for recalcitrant CRS. This article reviews recent
publications regarding endotypes and endotype-based therapeutic strategies in CRS and NP.
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INTRODUCTION
Chronic rhinosinusitis (CRS) is one of the common diseases
affecting about 10% of the general population, causing significant socioeconomic burden.1,2 The phenotypes of CRS, clinically observable characteristics, have been classified based on endoscopic or computed tomographic findings of nasal polyps
(NP),3 the presence of lower airway disease (e.g. aspirin-exacerbated respiratory disease), and hypersensitivity to allergens (e.g.
allergic fungal rhinosinusitis). Furthermore, CRS can also be
subdivided by underlying diseases, such as cystic fibrosis, ciliary dyskinesia, autoimmune diseases, immune deficiency, and
systemic illness.4-6 Specifically, NP are presented as a severe
form of inflammation and remodeling among the phenotypes
of CRS, and the presence of NP has been considered the most
important clinical aspect of phenotyping CRS due to therapeutic challenges. For this reason, histologic subtypes of NP have
been sought to be defined more precisely: eosinophilic or noneosinophilic NP. Mucosal eosinophilia predicts recurrence after
surgeries and risks of having comorbidities.7 However, there are
no standard methods to evaluate tissue eosinophilia due to uneven distribution throughout the tissue.8 Multiple inflammatory cells exist in most NP tissue, but the function and pathological roles of these cells are not yet completely elucidated.9 Even

in eosinophilic NP, neutrophils and macrophages exist and
may play a role in nasal polypogenesis.2 Therefore, the subtyping of CRS or NP based on inflammatory cells has limitations.
One phenotype can include several molecular mechanisms
(endotypes), and one endotype can also involve several phenotypes. Due to these challenges, it is hard to design a personalized treatment approach with clinical phenotyping or histologic subtyping alone.
The concept of personalized medicine in the field of CRS can
be incorporated after establishing endotypes. This is because
CRS involves various pathomechanisms showing high heterogeneity, which causes different therapeutic responses. Endotyping also helps determine optimal primary therapeutic modality, select a good responder to a specific treatment, and predict treatment outcomes and risks for comorbidities, such as
asthma.
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We herein summarize pathophysiology and potential endotypes of CRS with NP (CRSwNP) and introduce biologicals
available now or under investigation in CRS.

PATHOGENESIS AND ENDOTYPES OF CRS
Epithelial barrier function and epithelial cytokines
CRS can be understood as a dysfunctional host-environment
interaction at the nasal and sinus mucosa.10,11 Bacterial and viral infections, fungal extracts, and protease allergens play potential roles in CRS as external stimuli.12 For the evidence of
bacterial roles, the superantigen hypothesis has been strongly
suggested. Colonized Staphylococcus aureus secretes enterotoxins that augment local T helper 2 (Th2) inflammation and
may play a role in the pathogenesis of NP as a disease modifier
rather than an initiator.13 Another hypothesis of bacterial roles
is that bacterial biofilms may be involved in CRS pathogenesis.
Biofilms are organized structures comprised of bacteria protectively encased within extracellular matrix (ECM), which is associated with local inflammatory markers and disease severity.14
Although many studies have attempted to find evidence, the
role of fungi in CRS has drawn lots of controversies in the last
decade.15 There is still relatively sparse evidence that viral infection is a chronic source of CRS or involved in the initiation and
development of sinonasal allergic inflammation. However, dsRNA, a toll-like receptor 3 (TLR3) ligand, is a potent inducer of
thymic stromal lymphopoietin (TSLP)16 and a potential changer of innate lymphoid cell (ILC) phenotypes,17 which may be associated with chronicity of airway disease. Moreover, viral infection has been clearly implicated in the exacerbation of allergic airway diseases, such as asthma, in a number of studies.18
The epithelial barrier is the first line of defense; its breakdown
can play a significant role in allowing external stimuli to enter
nasal tissue and provoke immune responses.19 Functional and
mechanical defects have been reported in NP. The protease-activated receptor (PAR) contributes to the production of cytokines and chemokines from the epithelium in response to external stimuli, such as bacteria, fungi, and allergens.12,20 Epithelial barrier destroyed by protease activities enables allergens to
pass physical epithelial barriers, culminating in allergen sensitization.21 It also signals epithelial cells to secrete innate cytokines and then facilitates the induction of eosinophilic inflammation. Epithelial-derived innate cytokines, such as interleukin
(IL)-25, IL-33, and TSLP, may also participate in the evolution
of NP.22 IL-33 is secreted by immune cells, such as macrophages
and dendritic cells as well as epithelial cells.23 Full-length IL-33
is extracellularly released when epithelial cells undergo necrosis and necroptosis via tissue damage caused by external stimuli. Biologically active full-length IL-33 plays a role in mucosal
inflammation recruiting neutrophils via chemokines, including
chemokine (C-X-C motif) ligand (CXCL)-1 and CXCL-2.24-26
Gordon et al.27 have suggested a potential role of IL-33 in eosin-
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ophilic inflammation by demonstrating a splice variant of IL-33
missing exons 3 and 4, which localizes to the cytoplasm of epithelial cells, is actively released and strongly related to Th2 inflammation, whereas full length is not. Several studies have
sought to investigate the expression and role of IL-33 in CRS.
There have been conflicting results of the expression of IL-33 in
CRS. It has been reported that IL-33 mRNA is highly expressed
in nasal mucosa but was not elevated in NP or other inflamed
areas of the sinuses in CRSwNP.28-30 A significant up-regulation
of ST2 expression has been demonstrated in ethmoid mucosa
from CRSwNP, but the concentration of IL-33 protein is not significantly different between nasal polyp and control tissue.31
Kim et al.23 have recently demonstrated that IL-33 is up-regulated in other CRS tissues compared to eosinophilic NP and correlates with Th1/Th17 cytokines. IL-33 may contribute to the
induction of different types of inflammation under various microenvironments.
IL-17E, also known as IL-25, is released by Th2 cells, mast
cells, eosinophils as well as epithelial cells. It is produced and
stored in the cytoplasm of epithelial cells as a result of external
stimuli, including allergen proteases.32 IL-25 transcript levels
have been reported to increase in CRS tissues, including NP
and to correlate with disease severity and blood eosinophilia,30,33 whereas an earlier study has reported that IL-25 and GATA-binding protein 3 (GATA-3) transcripts were decreased in
NP vs control tissues.29 Additionally, polyp-derived IL-17RB (+)
Th2 cells were identified in NP, which co-expressed ST2 and
enhanced IL-5 and IL-13 production in response to IL-25 and
IL-33.34 Protein levels of IL-25 are up-regulated in non-eosinophilic NP as well as eosinophilic NP.22,35 Of note, the fact that IL25, known as a cytokine involved in diverse Th2-mediated diseases, also correlated with inflammatory mediators involved in
Th1 and Th17 responses in Asian subjects suggests that it may
play diverse roles in polypogenesis besides promoting Th2 inflammation.33,36 Blockade of IL-25 reduced the burden of NP in
a mouse model of NP and represented a potential novel therapeutic target.36
TSLP is well known to be induced in airway epithelial cells by
viruses, TLR3 agonists, protease, and pro-inflammatory cytokines.16,37-39 IL-1β and tumor necrosis factor (TNF)-α regulate
TSLP transcript expression in an nuclear factor-kappa B (NFκB)-dependent manner.39 Several researchers have demonstrated that TSLP mRNA is overexpressed in eosinophilic NP
and associated with Th2 inflammation.40-42 TSLP induces the
differentiation of naïve T cells into effector Th2 cells via enhancement of OX40 ligand (OX40L)-OX40 axis on the interaction between dendritic cells and CD4 T cells.43 TSLP protein is
post-translationally modified by the endogenous protease. The
cleaved TSLP shows higher activity, producing IL-5 when stimulated with IL-1β, than the full-length form.40 Of interest, Kim et
al.44 authors recently demonstrated that TSLP production was
induced by periostin in epithelial cells under the Th2 high in-

Allergy Asthma Immunol Res. 2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299

Precision Medicine in Chronic Rhinosinusitis

AAIR
flammatory condition like eosinophilic NP. Until now, TSLP has
been consistently reported to play a pathological role in eosinophilic NP unlike IL-25 and IL-33.
ILCs
Epithelial-derived cytokines, such as IL-25, IL-33, and TSLP,
exert effects on type 2 ILCs (ILC2s).45 ILCs are lymphocyte-like
cells, but lack markers of mature lymphocytes, and do not express allergen-specific T cell receptors. ILC2s are regarded as
innate counterparts of Th2 cells because both share the same
functional module by their mutual production of signature cytokines, such as IL-5 and IL-13.46 For example, GATA-3 is a key
transcriptional factor that plays parallel roles in the development and function of both Th2 cells and ILC2s.47 Moreover, the
signal transducer and activator of transcription (STAT)-6 is also
an important factor for Th2 polarization and plays a role in the
post-developmental role in ILC2s, though it is not required for
the development of ILC2s.46 Interestingly, IL-33- and IL-25-activated ILC2s can induce eosinophilic airway inflammation accompanied by airway hyperresponsiveness even in recombination-activating gene (Rag) knockout mice, which means ILC2s
have function independent of acquired immunity.48,49 ILC2s are
abundant and also have a close relationship with higher tissue
and blood eosinophilia in NP, clinically related to worsening
nasal symptom scores and asthma comorbidity.50,51 Bal et al.52
have reported that there is spatial co-localization between
ILC2s and eosinophils in NP, and that co-culture of eosinophils
and ILC2s augmented the activation of eosinophils and prolonged their survival, and in return pre-activated eosinophils
enhanced IL-5 production of ILC2s in an IL-4 dependent manner. Of note, ILC2s have functional plasticity responsive to environmental cues, including viral infection. Mouse ILC2s in the
lung undergo T-bet-mediated plasticity in response to infection, including influenza virus, respiratory syncytial virus, Haemophilus influenza, and Staphylococcal aureus.17 Human ILC2s
can be converted into ILC1s by IL-12 and reversed by IL-4,52 or
into interferon (IFN)-γ/IL-13 dual-producing ILC1s in response
to both IL-1β and IL-12.53 T cells that are able to produce both
IFN-γ and IL-13 induce enhanced airway hyperresponsiveness
compared to conventional Th2 cells.54 Thus, ILC2 plasticity may
contribute to disease heterogeneity which might lead to recalcitrance and exacerbation of inflammatory diseases.
T cell subsets
Three major subsets of CD4+ T effectors, classified as Th1,
Th2, and Th17, function in host defense in response to various
types of pathogens and are involved in different types of tissue
injury in immunologic diseases. Regulatory T cells (Tregs)
modulate T cell response inducing the termination of inflammation. Definite characteristics of differentiated subsets of T effector cells are cytokines they produce and transcriptional factors they express. Signature cytokines produced by the major

CD4+ T cell subsets are IFN-γ for Th1 cells; IL-4, IL-5, and IL-13
for Th2 cells; IL-17 and IL-22 for Th17 cells, and IL-10 and
transforming growth factor-beta (TGF-β) for Treg. Involved
transcriptional factors are T-bet for Th1, GATA-3 for Th2, retinoid-related orphan receptor C (RORC) for Th17, and FOXP3
for Treg. CRS was initially classified according to the presence
of NP which reflects predominantly eosinophil-infiltrating Th2
inflammation at the molecular levels in Western countries.55
However, Asian populations, including Chinese population,
showed multiple inflammatory cell infiltrates, including neutrophils and T cells classified as Th1/Th17 cells.56 Furthermore,
mixed Th17/Th2 inflammatory patterns were also demonstrated throughout a single nasal polyp tissue, and eosinophilic NP
also encompass neutrophils and their biological markers such
as IL-8 and myeloperoxidase.2 Therefore, NP begin to be understood from the dichotomization of Th1 or Th2 to a multi-dimensionally evolved concept. A European multicenter casecontrol study group (GA2LEN Sinusitis Cohort group) recently
conducted the clustering of CRS subjects by T cell subset-based
cytokines and explored whether these cytokines adequately reflect phenotype, such as the presence of NP or asthma comorbidities.57 This study analyzed tissue cytokines from 173 CRS
subjects and 89 controls in a phenotype-free manner and classified 10 clusters: 4 clusters with low or undetectable IL-5, immunoglobulin E (IgE), and eosinophilic cationic protein (ECP);
and 6 clusters having moderate to high concentrations of these
markers. In detail, cluster 1 has minimal inflammatory markers, cluster 2 associated with Th22, cluster 3 representing Th1,
and cluster 4 showing mixed Th17/Th22/Th1. The latter 6 clusters with elevated IL-5 were classified into 2 groups: clusters
8-10 showed the highest IL-5 with enhanced IgE against Staphylococcal enterotoxins plus neutrophilic markers plus Th17/
Th22 cytokines implying sophisticated pathomechanism,
whereas clusters 5-7 showed mainly IL-5 dominant CRS. This
clustering roughly reflects phenotypes: clusters 1-3 represent
CRS without NP (CRSsNP) and low asthma comorbidity, but
the proportion of NP and asthma comorbidities seems to increase from cluster 4 to cluster 10. Furthermore, it was reported
to be a distinct regional difference in endotypes.2 CRSwNP tissues from patients of European countries, such as Benelux and
Berlin, had a high proportion of IL-5 (62%-82%); those from
Adelaide, Australia showed IL-5 in 46% and mixed IL-5 plus IL17 or IFN-r in 27%. Most of the Western NP were Th2-biased.
However, there was a remarkable difference even in Chinese
NP. Beijing NP showed mixed IL-5/IL-17 portion of 42%; NP in
Chengdu, a Chinese city, mainly had a negative cytokine pattern of 57%. These results imply that CRS is not a dichotomous
disease but has multi-dimensional continuum worldwide. To
make this concept clearer and more understandable, longitudinal cohort studies would be required rather than cross-sectional, case-control studies conducted in the past.
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Remodeling
CRS is characterized by edematous remodeling patterns, basement membrane thickening, and goblet cell hyperplasia.58,59
TGF-β is not only a chemoattractant for fibroblasts, enhancing
their proliferation and collagen deposition, but also an inducer
for Treg. High TGF-β is characteristic for CRSsNP, but low TGF-β
was a signature finding in patients with CRSwNP.58,60 Low TGF-β
is also associated with a defect of Treg, namely, failing to maintain homeostasis, additionally, failure of deposition of collagens
and other ECMs. High matrix metallopeptidases (MMPs), which
are usually observed in NP, support ECM degradation.61 Besides
the roles of TGF-β in the remodeling process in NP, the dysregulated coagulation system can be engaged in this process. Coagulation and fibrinolysis cascades are the biological processes involved in fibrin deposition and dissolution.62 The first study to
suggest local activation of the coagulation system in sinus tissue
showed that the concentration of thrombin and thrombin-antithrombin complex were increased in CRSwNP, which in turn
participated in the remodeling process via a vascular endothelial growth factor pathway.63 Since that study, well-conducted reports have documented that the down-regulation of tissue plasminogen activator (t-PA) and activated coagulation factor XIIIa
are involved in fibrin deposition and enhancement of fibrin
crosslinking, culminating in edematous remodeling patterns in
NP.63-65 Of interest, the concentration of t-PA in CRS tissues
shows a negative correlation with the concentration of ECP, a
marker of eosinophils, and t-PA is mainly stained in epithelial
cells on immunohistochemistry and down-regulated in epithelial cells by Th2 cytokines, such as IL-4 and IL-13.64 Furthermore,
M2 macrophages, alternatively activated by Th2 cytokines,66
produce coagulation factor XIIIa which acts enzymatically and
contribute to the formation of a tight tetrameric complex (FXIIIA2B2), a cross-linking process of fibrin.65 In summary, Th2-induced coagulopathy causes excessive fibrin deposition to induce edematous remodeling patterns in NP. The pathogenesis
of NP described above is depicted in Figure.

PERSONALIZED THERAPEUTIC STRATEGIES
Therapeutic strategies according to clinical or pathologic
markers have also been developed. Among these signs, tissue
eosinophilia is the most important regarding disease recurrence and comorbidities.7 Approximately 70%-80% of CRSwNP
cases accounts for eosinophilic types in the Western country,
whereas 30%-40% cases constitute eosinophilic NP in Asian
countries, including South Korea and China.2,9 Eosinophilic
CRS is a better responder to steroid therapy vs non-eosinophilic CRS.67 Non-eosinophilic CRS seems to be a better responder
to surgical treatment vs eosinophilic CRS, especially in elderly
subjects.68 Therefore, how to discriminate between 2 groups by
using clinical features or easily available samples, such as blood
samples, has been investigated because tissue eosinophil count
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using biopsy tissue is not practical for primary care clinicians.
Blood eosinophilia, computerized tomography (CT) scans
showing ethmoidal dominance, bilateral disease, asthma comorbidity, and aspirin sensitivity are predictors of eosinophilic
NP.69,70 Despite strategical approaches according to histologic or
clinical subtypes, there must be mixed pathologic subgroups in
recalcitrant subgroups which require further innovative therapeutic plans. That is why endotyping and the development of
biologicals corresponding to their endotypes are inevitable at
present. When we determine molecular targets from previous
research data, Th2 cytokines, such as IL-4, IL-5, IL-13, and periostin, epithelial-derived cytokines, such as TSLP, IL-33, and IL25, IgE as an acquired immunity marker, and Th17 cytokines
such as IL-17a and IL-22, can be candidates for biologicals.
Among these, several human monoclonal antibodies became
commercially available or under clinical trials in allergic disease.
A humanized monoclonal anti-IgE antibody, omalizumab,
which binds to free IgE with high affinity, has been used in
moderate to severe allergic asthma in the US and Europe.71 Hanania et al.72 have demonstrated that periostin is a marker for
omalizumab responsiveness in patients with moderate to severe allergic asthma. Since the concentration of IgE is locally increased in eosinophilic NP,73 a strategy for antagonizing IgE
might be relevant in subjects with eosinophilic NP. However, a
clear indication of omalizumab remains undetermined in NP.74
Given that periostin is upregulated and secreted from mast
cells via IgE-mediated signaling in eosinophilic NP,44 periostin
might be a biomarker for responsiveness to omalizumab in eosinophilic NP. Gevaert et al.75 conducted a randomized, doubleblind, placebo-controlled study on the effects of omalizumab
on NP and comorbid asthma (n=24). A significant decrease in
the total nasal endoscopic polyp score after 16 weeks in the
omalizumab-treated group was observed. Omalizumab also
showed significant benefits in nasal and respiratory symptoms,
such as nasal congestion, anterior rhinorrhea, loss of smelling
sense, wheezing, and dyspnea, as well as quality-of-life scores,
irrespective of the presence of allergy. However, there was no
reduction in nasal or serum inflammatory mediators in the
treated group. Larger sizes of clinical trials are needed to confirm this proof-of-concept study and to analyze subgroups for
appropriate biomarkers to guide better treatment responses.
Eosinophils, mast cells, and ILC2s mainly produce IL-5 which
is a strong driver to Th2 inflammation and associated with a
higher risk of having asthma comorbidity.76 As mentioned
above, 80% of Western NP cases account for the eosinophilic
type. Furthermore, over 80% of European NP cases and 20%60% of Asian NP cases expressed IL-5 in NP tissue homogenates.2 Based on previous mechanistic studies, antagonizing
IL-5 would be considered a good therapeutic target. In a small
clinical trial, subjects treated with anti-IL-5 mAb (reslizumab)
showed reduced polyp size, blood eosinophilic counts, and
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ECP concentration in nasal secretions. Responders had higher
IL-5 levels in nasal secretions compared with non-responders.
However, there was no symptom improvement in the treated
group.77 A clinical trial of another anti-IL-5 mAb, mepolizumab,
demonstrated similar results as a previous study and showed a

significant reduction in polyp score, blood eosinophilic count,
serum ECP, and serum IL-5Rα, but no significant improvement
in symptom scores.78 based on earlier studies, it still remains
unclear which biomarker can be used to select good responders to anti-IL-5 treatment.
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Dupilumab targeting IL-4Rα has inhibitory effects on the signaling of IL-4 and IL-13 since both cytokines signaled through
IL-4Rα as a common subunit. IL-4 and IL-13 act through 2 different receptors. One is type 1, activated by IL-4 only and expressed on the lymphocyte. The other is type 2 receptor activated by both IL-4 and IL-13 and expressed by various cells.71
Blocking the type 2 receptor is promising for controlling recalcitrant allergic disease.79,80 Since type 2 receptors can play a pivotal role in polypogenesis, dupulimab may play a role in treating
recalcitrant NP. Recently, a multi-center clinical trial demonstrated a potential role of dupilumab in NP showing a significant decrease in nasal polyp score and improvements in olfaction and CT scores as well as other clinical outcomes, such as
nasal symptoms and quality of life.81
Epithelial cell-derived innate cytokines, including TSLP, exert
major effects on Th2 inflammation. However, there has been
no study regarding its effect on NP, although a previous study
investigated the inhibitory effects of anti-TSLP on allergen-induced asthmatic response.82 The roles of IL-25 and IL-33 in NP
remain unclear and need further investigation.83 Therefore, targeting epithelial derived innate cytokines can be promising because it may control upstream mediators which T cell subsets
do not act on.

CONCLUSIONS
A clinically observable phenotype includes multiple molecular endotypes with different prognoses. Therefore, phenotyping
is not sufficient to predict responsiveness to medical or surgical
treatments and the risk of comorbid conditions. With the advent of an era with biologicals, endotyping helps select patients
suitable for each biological which can be a breakthrough in
treating NP. Although modulating acquired immunity, for example T cell subsets, has made some progression, targeting epithelial cell-derived innate cytokines, such as TSLP, IL-33, and
IL-25, may provide novel opportunities to manage CRS and NP
as well as allergic airway disease.
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